Myopia and axial length in school-aged children before, during, and after the COVID-19 lockdown-A population-based study. 2022

Wei Pan, and Jiang Lin, and Li Zheng, and Weizhong Lan, and Guishuang Ying, and Zhikuan Yang, and Xiaoning Li
Aier Institute of Optometry and Vision Science, Aier Eye Hospital Group, Changsha, China.

Myopic shift had been observed during the COVID-19 lockdown in young school children. It remains unknown whether myopic shift is accompanied with increase in axial length. We aimed to evaluate the impact of the COVID-19 lockdown on myopia and axial length of school children in China by comparing them before, during and after the lockdown. In this population-based cross-sectional study, school-based myopia screenings were conducted in the Fall of 2019, 2020, and 2021 (representing before, during and after COVID-19 lockdown respectively) in Chengdu, China. Myopia screenings were performed on 83,132 students aged 6 to 12 years. Non-cycloplegic refractive error was examined using NIDEK auto-refractor (ARK-510A; NIDEK Corp., Tokyo, Japan) and axial length was measured using AL-Scan (NIDEK Corp., Tokyo, Japan). Spherical equivalent (SER, calculated as sphere+ 0.5*cylinder), prevalence of myopia (SER ≤ -0.50 D), and axial length were compared across 3 years stratified by age. Myopia prevalence rate was 45.0% (95% CI: 44.6-45.5%) in 2019, 48.7% (95% CI: 48.3-49.1%) in 2020, and 47.5% (95% CI: 47.1-47.9%) in 2021 (p < 0.001). The mean non-cycloplegic SER (SD) was -0.70 (1.39) D, -0.78 (1.44) D, and -0.78 (1.47) D respectively (p < 0.001). The mean (SD) axial length was 23.41 (1.01) mm, 23.45 (1.03) mm, and 23.46 (1.03) mm across 3 years respectively (p < 0.001). From the multivariable models, the risk ratio (RR) of myopia was 1.07 (95% CI: 1.06-1.08) times, the SER was 0.05 D (95% CI: 0.04 D to 0.06 D) more myopic and the mean axial length increased by 0.01 mm (95% CI: 0.01 mm to 0.02 mm) in 2020 compared to 2019. In 2021, the risk ratio (RR) of myopia was 1.05 (95% CI: 1.04-1.06), the mean SER was 0.06 D (95% CI: 0.05 D to 0.07 D) more myopic, and the mean axial length increased by 0.03 mm (95% CI: 0.02 mm to 0.04 mm) compared to 2019. The COVID-19 lockdown had significant impact on myopia development and axial length, and these impacts remained 1 year after the lockdown. Further longitudinal studies following-up with these students are needed to help understand the long-term effects of COVID-19 lockdown on myopia.

UI MeSH Term Description Entries
D009216 Myopia A refractive error in which rays of light entering the EYE parallel to the optic axis are brought to a focus in front of the RETINA when accommodation (ACCOMMODATION, OCULAR) is relaxed. This results from an overly curved CORNEA or from the eyeball being too long from front to back. It is also called nearsightedness. Nearsightedness,Myopias,Nearsightednesses
D012029 Refraction, Ocular Refraction of LIGHT effected by the media of the EYE. Ocular Refraction,Ocular Refractions,Refractions, Ocular
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D003140 Communicable Disease Control Programs of surveillance designed to prevent the transmission of disease by any means from person to person or from animal to man. Flatten the Curve of Epidemic,Flattening the Curve, Communicable Disease Control,Parasite Control,Control, Communicable Disease,Control, Parasite
D003430 Cross-Sectional Studies Studies in which the presence or absence of disease or other health-related variables are determined in each member of the study population or in a representative sample at one particular time. This contrasts with LONGITUDINAL STUDIES which are followed over a period of time. Disease Frequency Surveys,Prevalence Studies,Analysis, Cross-Sectional,Cross Sectional Analysis,Cross-Sectional Survey,Surveys, Disease Frequency,Analyses, Cross Sectional,Analyses, Cross-Sectional,Analysis, Cross Sectional,Cross Sectional Analyses,Cross Sectional Studies,Cross Sectional Survey,Cross-Sectional Analyses,Cross-Sectional Analysis,Cross-Sectional Study,Cross-Sectional Surveys,Disease Frequency Survey,Prevalence Study,Studies, Cross-Sectional,Studies, Prevalence,Study, Cross-Sectional,Study, Prevalence,Survey, Cross-Sectional,Survey, Disease Frequency,Surveys, Cross-Sectional
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000086382 COVID-19 A viral disorder generally characterized by high FEVER; COUGH; DYSPNEA; CHILLS; PERSISTENT TREMOR; MUSCLE PAIN; HEADACHE; SORE THROAT; a new loss of taste and/or smell (see AGEUSIA and ANOSMIA) and other symptoms of a VIRAL PNEUMONIA. In severe cases, a myriad of coagulopathy associated symptoms often correlating with COVID-19 severity is seen (e.g., BLOOD COAGULATION; THROMBOSIS; ACUTE RESPIRATORY DISTRESS SYNDROME; SEIZURES; HEART ATTACK; STROKE; multiple CEREBRAL INFARCTIONS; KIDNEY FAILURE; catastrophic ANTIPHOSPHOLIPID ANTIBODY SYNDROME and/or DISSEMINATED INTRAVASCULAR COAGULATION). In younger patients, rare inflammatory syndromes are sometimes associated with COVID-19 (e.g., atypical KAWASAKI SYNDROME; TOXIC SHOCK SYNDROME; pediatric multisystem inflammatory disease; and CYTOKINE STORM SYNDROME). A coronavirus, SARS-CoV-2, in the genus BETACORONAVIRUS is the causative agent. 2019 Novel Coronavirus Disease,2019 Novel Coronavirus Infection,2019-nCoV Disease,2019-nCoV Infection,COVID-19 Pandemic,COVID-19 Pandemics,COVID-19 Virus Disease,COVID-19 Virus Infection,Coronavirus Disease 2019,Coronavirus Disease-19,SARS Coronavirus 2 Infection,SARS-CoV-2 Infection,Severe Acute Respiratory Syndrome Coronavirus 2 Infection,COVID19,2019 nCoV Disease,2019 nCoV Infection,2019-nCoV Diseases,2019-nCoV Infections,COVID 19,COVID 19 Pandemic,COVID 19 Virus Disease,COVID 19 Virus Infection,COVID-19 Virus Diseases,COVID-19 Virus Infections,Coronavirus Disease 19,Disease 2019, Coronavirus,Disease, 2019-nCoV,Disease, COVID-19 Virus,Infection, 2019-nCoV,Infection, COVID-19 Virus,Infection, SARS-CoV-2,Pandemic, COVID-19,SARS CoV 2 Infection,SARS-CoV-2 Infections,Virus Disease, COVID-19,Virus Infection, COVID-19

Related Publications

Wei Pan, and Jiang Lin, and Li Zheng, and Weizhong Lan, and Guishuang Ying, and Zhikuan Yang, and Xiaoning Li
January 2023, PloS one,
Wei Pan, and Jiang Lin, and Li Zheng, and Weizhong Lan, and Guishuang Ying, and Zhikuan Yang, and Xiaoning Li
December 2021, Indian journal of ophthalmology,
Wei Pan, and Jiang Lin, and Li Zheng, and Weizhong Lan, and Guishuang Ying, and Zhikuan Yang, and Xiaoning Li
December 2022, The British journal of ophthalmology,
Wei Pan, and Jiang Lin, and Li Zheng, and Weizhong Lan, and Guishuang Ying, and Zhikuan Yang, and Xiaoning Li
January 2023, Journal of pediatric ophthalmology and strabismus,
Wei Pan, and Jiang Lin, and Li Zheng, and Weizhong Lan, and Guishuang Ying, and Zhikuan Yang, and Xiaoning Li
March 2021, JAMA ophthalmology,
Wei Pan, and Jiang Lin, and Li Zheng, and Weizhong Lan, and Guishuang Ying, and Zhikuan Yang, and Xiaoning Li
September 2021, JAMA,
Wei Pan, and Jiang Lin, and Li Zheng, and Weizhong Lan, and Guishuang Ying, and Zhikuan Yang, and Xiaoning Li
October 2021, Acta paediatrica (Oslo, Norway : 1992),
Wei Pan, and Jiang Lin, and Li Zheng, and Weizhong Lan, and Guishuang Ying, and Zhikuan Yang, and Xiaoning Li
January 2022, International journal of public health,
Wei Pan, and Jiang Lin, and Li Zheng, and Weizhong Lan, and Guishuang Ying, and Zhikuan Yang, and Xiaoning Li
February 2021, Preventive medicine,
Wei Pan, and Jiang Lin, and Li Zheng, and Weizhong Lan, and Guishuang Ying, and Zhikuan Yang, and Xiaoning Li
August 2021, International journal of environmental research and public health,
Copied contents to your clipboard!